Kerbala Journal of Pharmaceutical Sciences

ISSN: 2221-7207(Print) / ISSN: 3006-7189 (Online)



Correlation Of IL-5 And IL-17 With Specific Allergens in Pediatric Asthmatic Patients

Khalid J.Salem^{1*}, Alaa S. Alattabi², Dhamiaa M. Hamza², Haidar A. N. Abood³

¹ Department of Microbiology, College of Science, Al-Mustansirya University, Baghdad, Iraq

*Corresponding Author

Khalid J.Salem: khalid.j@s.uokerbala.edu.iq.

Received:27/01/2025 Accepted:22/02/2025 Published:30/06/2025

Keywords: Asthma, Immunity, IL-17, IL-5, Pediatrics



DOI: 10.62472/kjps.v16.i26.240-252

Abstract

Background: This study aimed to investigate the correlation between interleukin-5 (IL-5) and interleukin-17 (IL-17) with specific aeroallergens in pediatric asthmatic patients.

Patients and Methods: A cross-sectional study included (100) pediatric asthmatic patients, focusing on demographics, Biomarkers, and aeroallergens.

Results: The results showed that eosinophilic asthma patients had considerably higher levels of IL-5 (p=0.0015), especially those who were sensitized to allergens like sorrel, white ash, and sweet vernal mix. IL-17 levels were associated with sensitivity to firebush and CCD indicators and were higher in neutrophilic asthma (p=0.0072). Overlapping biomarker elevations in mixed granulocytic asthma suggested intricate inflammatory processes.

Conclusion: The significance of IL-5 and IL-17 as biomarkers for asthma phenotype in juvenile patients is highlighted by this study. IL-5 plays a crucial role in allergen-induced asthma, as seen by the strong association it has with particular allergens. Asthma treatment could be completely transformed by personalized therapy based on biomarker analysis.

² Department of Medical Microbiology, College of Medicine, University of Kerbala, Karbala/Iraq

³Department of Pharmacology, College of Medicine, University of Kerbala, Karbala, Iraq

العلاقة بين 5-IL و 17-IL ومسببات الحساسية المحددة لدى مرضى الربو الأطفال خالد جبار سالم، الاء سعد العتابى، ضمياء مكى حمزة، حيدر عبد الامير نجم عبود

الخلاصة

المقدمة

هدفت هذه الدراسة إلى دراسة العلاقة بين الإنترلوكين-5 (IL-1) والإنترلوكين-17 (IL-11) مع مسببات الحساسية الجوية المحددة لدى مرضى الربو الأطفال.

المرضى وطرق العمل

شملت هذه الدراسة المقطعية (100) مريضًا بالربو من الأطفال، مع التركيز على التركيبة السكانية والعلامات الحيوية ومسببات الحساسية الجوية.

النتائج

أظهرت النتائج أن مرضى الربو الحمضي لديهم مستويات أعلى بكثير من (p=0.0015) وخاصة أولئك الذين كانوا حساسين لمسببات الحساسية مثل الحميض والرماد الأبيض ومزيج الربيع الحلو. ارتبطت مستويات P=0.0072 بالحساسية لمؤشرات شجيرة النار وP=0.0072 وكانت أعلى في الربو العدلي (P=0.0072). تشير ارتفاعات المؤشرات الحيوية المتداخلة في الربو الحبيبي المختلط إلى عمليات التهابية معقدة.

الاستنتاج

وُجِد في هذه الدراسة أهمية 5-IL و 17-IL كعلامات حيوية لنمط الربو لدى المرضى الأحداث. يلعب 5-IL دورًا حاسمًا في الربو الناجم عن المواد المسببة للحساسية، كما يتضح من الارتباط القوي الذي له بمسببات الحساسية المحددة. يمكن تحويل علاج الربو تمامًا من خلال العلاج الشخصى القائم على تحليل العلامات الحيوية.

1. Introduction

Asthma, a chronic respiratory disorder that affecting over 300 million individuals worldwide, is still particularly prevalent among children with significant morbidity and economic burden (Levy *et al.*, 2023). This disorder condition is characterized by hyper responsiveness of airway, obstruction, and persistent inflammation driven by diverse immunological pathways. In pediatric; asthma often manifested in distinct phenotypes, including eosinophilic and neutrophilic asthma each of them associated with the inflammatory profiles (Wenzel, 2012). Interleukin-5 (IL-5) a cytokine pivotal to eosinophilic inflammation that promoting eosinophil differentiation with activation and survival (Takatsu, 2011). In the context, interleukin-17 (IL-17) Produced by Th17 cells, IL-17 has been implicated in neutrophilic asthma and associated with the severe and steroid-resistant asthma in patients (Rahmawati *et al.*, 2021). Association of biomarkers with environmental allergens, such as pollen and animal dander were recognized as primary triggers for asthma exacerbations especially in atopic individuals. Interleukin-5 is closely associated with to allergen driven eosinophilic inflammation, while interleukin-17 had role extends to non-atopic triggers such as pollution and infections (Hammad and Lambrecht, 2021). This study aims to investigate the association between IL-5, IL-17, and specific allergens to enhance asthma diagnosis and allocate appropriate treatments.

2. Material and Methods

2.1. Study Design

A cross-sectional study included 100 pediatric asthmatic patients aged from 6 to 15 years. Participants were divided into four group asthma phenotypes: (eosinophilic, neutrophilic, mixed granulocytic, and allergic asthma).

2.2. Inclusion Criteria

- 1. Diagnosed asthmatic children aged (6-15) years.
- 2. Children is receiving inhaled corticosteroids.

2.3. Exclusion Criteria

- 1. Patients on systemic corticosteroids or biologic therapy.
- 2. All patients' upper and lower respiratory infection diseases.
- 3. Patients with autoimmune disease and these with cystic fibrosis also should be excluded.

2.4. Data Collection and Analysis

- 1. Demographic and Clinical data will be collected using a specific detailed questionnaire
- 2. Approximately 5 ml of venous blood were drawn from each subject which were obtained by disinfecting antecubital fossa with 70% ethanol and then make vein puncture by disposal syringes after applying a tourniquet. One ml of blood was dispensed into (1) EDTA tube for the haematological tests. Four ml of blood was dispensed into gel tube and allowed to clot then serum was separated by centrifugation at

3000 round per minutes (RPM) for 5 minutes. Then the serum was transferred to new eppendorf tube (2 ml) and stored in deep freeze (-20°C) to be used for immunological assays.

- 3. Immunological measurement of IL-5, IL-17, and specific IgE (S.IgE) by ELISA Kit
- **4.** The study was used Enzyme-linked immunosorbent assay (ELISA): for biomarkers IL5, IL17 ,total IgE (T.IgE) and specific immunoglobulin E (S.IgE) inhalation in peripheral blood for all patients
- **5.** Correlation between biomarkers and allergen sensitivity was analyzed.

2.5. Ethical Considerations

Ethical approval was obtained from the Karbala College of Medicine and patient consent was secured.

2.6. Statistical Analysis

Statistical analysis of data in the present study was performed by SPSS. version 25.0 on the basis of one way analysis of variance (ANOVA) using significant levels (P<0.05).

3. Results

3.1. Demographic Data for Asthma Patients

The demographic data of asthmatic patients were included in current study were illustrated in Table (3-1). These data were involved: age, sex, residency, passive smoking, family history, Food allergy, Allergic Rhinitis, and Pets at home. patients were divided according to their ages into three groups: 5-8 y, 9-12 y, and 13-16 y, the results of statistical analysis using Chi-square test revealed a highly significant (p=0.0001) differences between groups, where the highest percent (58.0%) of patients within the age group 9-12 y. The majority (72.5%) of asthma patients were male, while only (27.5%) were female, the results of statistical analysis showed a highly significant (p=0.0001) difference. In the context of residency, a significantly (p=0.0009) highest percent (66.4%) of patients were resided in urban, while only (33.6%) resided in rural. As for passive smoking, patients were divided into two groups: non-passive smoking and passive smoking, but statistical analysis did not show any significant differences between the two groups; where p=0.3173. Regarding family history; significantly (p=0.0001), most patients (70.2%) had a family history of asthma, while only 29.8% had no family history of the disease. As for food allergy, patients were divided into two groups according to present or absent food allergy. The results of the statistical analysis showed that the majority (82.4%) of patients in the current study did not have food allergy, while the smaller percentage (17.6%) had a food allergy; p=0.0001. with respect to Allergic Rhinitis and presence a pet at home, the results of statistical analysis found non-significant (p>0.05) differences between groups of asthma patients divided according to these mentioned characteristics as, as shown in Table 1.

Table1: Demographic Data for Asthma Patients

	A	ge group (year)						
	5-8 y	9-12 y	13-16 у	Total	P value			
Count (%)	29(29%)	59(59%)	12(12%)		0.0001*			
Mean ± SD		9.71 ± 2.328						
		Gender						
	Male	Fem	ale	Total	P value			
Count (%)	75 (75%)	25(25	5%)	100	0.0001*			
		Residency						
	Urban	Rur	al	Total	P value			
Count (%)	65 (65%)	35(35	5%)	100	0.0027^{*}			
	P	assive Smoking						
	Non-2nd smoking	2nd sm	oking	Total	P value			
Count (%)	52(52%)	48 (4)	48 (48%)		0.6892			
		Family Hx						
	Non- Family hX	Famil	y hX	Total	P value			
Count (%)	30 (30%)	70 (70	0%)	100	0.0001^*			
		Food allergy						
	Non- food allergy	Food a	llergy	Total	P value			
Count (%)	82(82%)	18 (1	8%)	100	0.0001*			
	A	Illergic Rhinitis						
	Non-allergic Rhinitis	Allergic 1	Rhinitis	Total	P value			
Count (%)	43(43%)	57 (5'	7%)	100	0.1615			
		Pets at home						
	No	Ye	S	Total	P value			
Count (%)	48(48%)	52(52	2%)	100	0.6892			
*Mean significar	t difference P< 0.05 level by	y chi-square test			·			

3.2. Biomarkers Concentrations in Asthma Patients

3.2.1. Biomarkers Concentrations in Asthma Patients According to Eosinophilic Group

Table2 displays the concentrations of studied markers (IL-17, IL-5) according to Eosinophilic group (Eosinophil scores) in asthmatic patients, which divided into three groups: high, low and normal. Statistical analysis using one way-ANOVA test showed non-significant (p>0.05) differences in the distributions of IL-17, while highly significant (P=0.0015 and P=0.0054 respectively) for IL-5.

Table2: Biomarkers Concentrations in Asthma Patients According to Eosinophil Scores

Biomarkers/units	Eosinophil	No.		concentration atients	P value
	level		Mean	Std. Deviation	
	High	65	221.54969	112.862866	
H 17 (1)	Low	14	184.11750	108.190582	0.212
IL-17 (unit)	Normal	21	255.21229	133.607551	0.212
	Total	100	223.37833	117.529254	
	High	65	262.74848	194.840479	
TT 5 ('4)	Low	14	142.91371	45.396255	0.0015*
IL-5 (unit)	Normal	21	196.93794	141.376216	0.0015*
	Total	100	203.19476	148.838171	
*Mean significant d	ifference $p \le 0$.	05 by Or	ne way – ANOVA		

3.2.2.Biomarkers Concentrations in Asthma Patients According to Neutrophil Scores

Table3 shows the concentrations of studied markers (IL-17, IL-5) according to Neutrophil scores in asthma patients, which divided into three groups: high, low and normal. Statistical analysis using one way-ANOVA test showed highly-significant (P=0.0072 respectively) for IL-17 while for these markers IL-5 there was no significant

Table3: Biomarker Concentration in Patients According to Neutrophil Levels

Tables. Biolinarker Concentration in Tatients According to Neuropini Levels								
	Neutrophil		Biomarker	P value				
Biomarkers/units	level	No.	in p					
	levei		Mean	Std. Deviation				
	High	32	200.51786	288.88537				
IL-17 (unit)	Low	34	153.85226	218.18139	0.0072*			
	Normal	34	195.29070	285.54717	0.0072			
	Total	100	200.05798	246.69868				
	High	32	167.40991	412.99727				
W 5 ('A)	Low	34	124.63665	536.83347	0.416			
IL-5 (unit)	Normal	34	89.64867	302.64733	0.416			
	Total	100	187.51196	354.87756				
*Mean significant difference $p \le 0.05$ by One way – ANOVA								

3.2.3.Biomarkers Concentrations in Asthma Patients According to Mix Granulocytic Score

Table4 shows the concentrations of studied markers (IL-17, IL-5) according to mix granulocytic score in asthmatic patients, which divided into two groups: Mix and non-mix. Statistical analysis using one way-ANOVA test showed highly-significant (P=0.0074, P=0.0021) for IL-17, IL-5.

Table4: Biomarker Concentration in Patients According to Mix Granulocytic Score

Biomarkers/units	mix granulocytic	No.	Biomarker co		P value
	score	- 1,57	Mean	Std. Deviation	
	Mix	22	274.02077	134.435195	
IL-17	Non	78	209.09456	109.047451	0.0074*
	Total	100	223.37833	117.529254	
	Mix	22	412.86282	600.165762	
IL-5	Non	78	231.23710	350.852946	0.0021*
	Total	100	271.19476	421.742178	
*N	Mean significant dif	ference	$p \le 0.05$ by One wa	y – ANOVA	

3.4. Frequencies of All Aeroallergens (Aag) in Asthma Patients

The frequencies of all (Aag) in asthma patients were illustrated in Table 5. The results of the statistical analysis using chi-square test, indicated that the percentages of patients without antigens were significantly (p=0.0001) higher than those with (Aag), and this applies to all (Aag) included in the current study. The highest frequency (Aag) among asthma patients in the current study were Cat (18%), cultivated oat (17%) Meadow foxtail (19%), Goosefoot (15%), Russian thistle (22%), Rough pigweed (16%), Cockroach Germany (9%) and Altrenaria Altrenaria(12%)

Table5: Frequency of all Aeroallergens in Asthma Patients

Aeroallerg	ens	Count	%	Total	P value
Cat	Positive	18	18%		0.0001
Cat	Negative	82	8 %	100	0.0001
Cultivated oat	Positive	17	17 %		0.0001
Cultivated oat	Negative	83	83%	100	0.0001
Meadow foxtail	Positive	19	19 %		0.0001
Wieadow Ioxtaii	Negative	81	81%	100	0.0001
Goosefoot	Positive	15	15%		0.0001
Goosefoot	Negative	85	85%	100	0.0001
Russian thistle	Positive	22	22%		0.0001
Russian unsue	Negative	78	78 %	100	0.0001
Rough pigweed	Positive	16	16 %		0.0001
Rough pigweeu	Negative	84	84%	100	0.0001
Cockroach Germany	Positive	9	9 %		0.0001
Cocki bacii Germany	Negative	91	91%	100	0.0001
Alternaria	Positive	12	12%		0.0001
Aitei liai la	Negative	88	88%	100	0.0001
	Significant difference	e P< 0.05 level	by chi-square	test	

3.3. Biomarkers Concentration in Patients According to Aeroallergens

3.3.1. Biomarkers Concentration in Patients According to Aeroallergens (Sweet Vernal Mix).

Table6 shows the effects of Aeroallergen (Sweet vernal mix) on the biomarker's concentration of asthmatic patients. The results of the statistical analysis showed that highly significant in IL-5 (P=0.002), were is it increased in patients that have inhaled (<u>positive</u>) Aeroallergen (Sweet vernal mix). While other remaining biomarkers did not show any significant IL-17 (P=0.421).

Table6: Biomarkers Concentration in Patients According to Aeroallergens (Sweet Vernal Mix)

Biomarkers/units	Aeroallergen	N	Biomarker concentration in patients		P value
	(Sweet vernal mix)		Mean	Std. Deviation	
IL-17	Positive	13	219.70298	115.652329	
	Negative	78	247.97492	131.709794	0.421
	Total	100	223.37833	117.529254	
	Positive	13	597.63077	861.481380	
IL-5	Negative	78	222.41697	287.545651	0.002*
	Total	100	271.19476	421.742178	
	* Significant differer	$ce p \le 0$.05 by One way -	- ANOVA	

3.3.2. Biomarkers Concentration in Patients According to Aeroallergens (Firebush).

Table7 shows the effects of Aeroallergen (Sweet vernal mix) on the biomarker's concentration of asthmatic patients. The results of the statistical analysis showed that significantly in biomarkers IL-17 (P=0.003 respectively), were is it increased in patients that have inhaled (positive) Aeroallergen (Firebush). While the other remaining biomarkers did not show any significant IL-5 (P=0.210)

Table7: Biomarkers Concentration in Patients According to Aeroallergens (Firebush)

Aeroallergen/(Firebush) Positive Negative	10 90	Mean 231.52541 150.05460	Std. Deviation 118.741221	P value
Negative	90	150.05460		
		130.03400	76.672808	0.003*
Total	100	221.38722	113.128273	
Positive	10	111.88650	49.079889	
Negative	90	288.89568	440.952878	0.210
Total	100	261.17474	430.651267	
	Total	Total 100	Total 100 261.17474	Ŭ

3.3.3. Biomarkers Concentration in Patients According to Aeroallergens (Sorrel)

Table8 shows the effects of Aeroallergen (Sorrel) on the biomarker's concentration of asthmatic patients. The results of the statistical analysis showed that significantly only in IL-5 (P=0.004), were is it increased in patients that have inhaled (positive) Aeroallergen (Sorrel). While the other remaining biomarkers did not show any significant SAA1 and IL-17 (P=0.317 and P=0.244)

Table8: Biomarkers Concentration in Patients According to Aeroallergens (Sorrel)

Biomarkers/units	Aeroallergen (Sorrel)	Aeroallergen N		Biomarker concentration In patients		
		11	Mean	Std. Deviation	- P value	
	Positive	4	220.57337	116.632690		
IL-17	Negative	96	290.69725	137.008823	0.244	
	Total	100	203.24836	107.332244		
IL-5	Positive	4	684.58900	1026.119471		
	Negative	96	253.97000	380.276282	0.004*	
	Total	100	273.17446	441.766168		
	* Significant differen	ce p ≤ 0	.05 by One way -	- ANOVA	•	

3.3.4. Biomarkers Concentration in Patients According to Aeroallergens (White Ash)

Table 9 shows the effects of Aeroallergen (White ash) on the biomarker's concentration of asthmatic patients. The results of the statistical analysis showed that highly significant in IL-5 (P=0.006), were is it increased in patients that have inhaled (positive) Aeroallergen (White ash). While the other remaining biomarkers did not show any significant IL-17 (P=0.306)

Table9: Biomarkers Concentration in Patients According to Aeroallergens (White Ash)

Biomarkers/units	Aeroallergen	No.	Biomarker concentration in patients		P value
Diomarkers/units	(White ash)	110.	Mean	Std. Deviation	
	Positive	7	220.05989	115.792100	
IL-17	Negative	93	267.46614	141.038177	0.306
112-17	Total	100	221.656315	113.459334	
	Positive	7	688.49429	936.238586	0.006*
IL-5	Negative	93	239.78512	346.391350	0.000
	Total	100	241.29467	454.743848	
	* Significant differen	$ce p \le 0$.05 by One way -	- ANOVA	

3.3.5. Biomarkers Concentration in Patients According to Aeroallergens (Tree Mix 4)

Table 10 shows the effects of Aeroallergen (Tree Mix 4) on the biomarker's concentration of asthmatic patients. The results of the statistical analysis showed that significantly in IL-5 (P=0.005), were is it increased in patients that have inhaled (positive) Aeroallergen (Tree Mix 4). While the other remaining biomarkers did not show any significant IL-17 (P=0.640).

Table10: Biomarkers Concentration in Patients According to Aeroallergens (Tree Mix 4)

Biomarkers/units	Aeroallergen (Tree Mix 4)	N		r concentration patients	P value
	(Tree MIX 4)		Mean	Std. Deviation	
	Positive	4	222.24922	117.558341	
IL-17	Negative	96	250.47700	131.076512	0.640
	Total	100	213.67599	117.765844	
IL-5	Positive	4	673.42075	1168.957312	
	Negative	96	254.43534	367.570818	0.005*
	Total	100	272.19825	411.747654	
* Significant differer	nce $p \le 0.05$ by One w	ay – ANC	OVA		

3.3.6. Biomarkers Concentration in Patients According to Aeroallergens (CCD Markers)

Table11 shows the effects of Aeroallergen (CCD markers) on the biomarker's concentration of asthmatic patients. The results of the statistical analysis showed that significantly in IL17 (P=0.005), were is it increased in patients that have inhaled (positive) Aeroallergen (CCD markers). While the IL-5 did not show any significant (P=0.169).

Table11: Biomarkers Concentration in Patients According to Aeroallergens (CCD Markers)

Biomarkers/units	Aeroallergen (CCD		/iinite i		Biomarker concentration in patients		P value
	markers)		Mean	Std. Deviation			
	Positive	4	335.19400	90.970187			
IL-17	Negative	96	218.71934	116.554841	0.005*		
1L-1/	Total	100	226.74823	117.67214	0.005		
	Positive	4	259.32618	408.248584			
IL-5	Negative	96	556.04075	692.183039	0.169		
	Total	100	270.19476	421.742178			
* Significant differe	nce $p \le 0.05$ by One way	- ANO	VA				

ROC Analysis Receiver operating characteristic (ROC) analysis demonstrated that IL-5 and periostin have high predictive potential for identifying eosinophilic asthma phenotypes in allergen-positive patients, Table 12.

Table12: ROC Analysis of Biomarkers in Patients According to S. Ige

Biomarkers/units	AUC	Sensitivity	Specificity	Cut-off	P-value
IL-17	0.536	0.516	0.694	190.837	0.549
IL-5 0.569 0.406 0.75 168.474 0.251					
* Significant differen	ce p $\leq 0.05 1$	oy One way – ANOV	⁷ A		

4. Discussion

Demographic Characteristics and Asthma Prevalence

The current study's demographic analysis highlighted key factors influencing on asthma prevalence and severity in children. The significant proportion of asthmatic patients fall within the (9-12) years age group (58% with p=0.0001) suggesting potential vulnerability in this age group may be due to hormonal changes. The predominant of male patients (72.5%, p=0.0001) aligns with previous study that indicating that boys have tighter airways during early childhood, making them at risk to asthma exacerbation (Ricciardolo *et al.*, 2023). Regarding urban residency was significantly associated with asthma prevalence (65%, p=0.0009). This belongs to urban area had greater air pollutants and allergens. However, passive smoking has been a risk factor for respiratory and allergic conditions in children (Kim, Vazquez and Cubbin, 2023). A strong familial predisposition to asthma (70.2%, p=0.0001) caused by genetic component. This aligns with the findings of Cookson et al., (2011) who recognized genetic polymorphisms associated with IgE levels and airway inflammation. As well as, food allergies were less common among those patients (17.6%, p=0.0001) so that suggesting that aeroallergens rather than ingested allergens play a more important role in triggering asthma.

Biomarkers and Inflammatory Profiles

Elevated IL-5 levels in patients with high eosinophil scores (p=0.0015) explained its role in driving eosinophilic inflammation. IL-5 contributes to eosinophil differentiation and activation, leading to airway hyperresponsiveness and mucus overproduction. These findings confirmed the utility of IL-5-targeted therapies such as mepolizumab in managing eosinophilic asthma (Hammad and Lambrecht, 2021).

Neutrophilic Asthma: In line with its function in neutrophil recruitment and activation, IL-17 levels were considerably greater in individuals with high neutrophil scores (p=0.0072). For severe asthma phenotypes that frequently do not respond to corticosteroid treatment, this discovery is especially pertinent. For these individuals, targeted treatments like anti-IL-17 monoclonal antibodies could provide novel therapeutic options (Yang *et al.*, 2018). Mixed granulocytic asthma had a significantly higher IL-5 concentration (412.86 \pm 600.17 units) than non-mixed phenotypes (231.23 \pm 350.85 units, p = 0.0021). Although IL-5 is a marker of eosinophilic inflammation, its increased level in individuals with mixed phenotypes could be a reflection of the overlapping inflammatory processes that these patients have. Chu *et al.*, (2015) discovered that a significant decrease in lung activating and chemotactic cytokines, namely IL-17A and IL-5, was linked to the prevention of neutrophilic and eosinophilic inflammation.

Aeroallergen Sensitivity and Biomarker Expression

The study highlighted the significance of environmental triggers in asthma exacerbations by identifying a number of aeroallergens with strong correlations to biomarker levels. IL-5 with Aeroallergens: Patients who were exposed to aeroallergens such white ash (p=0.006), sorrel (p=0.004), and sweet vernal mix (p=0.002) had higher levels of IL-5. According to these results, these allergens are important targets for allergen-specific immunotherapy as they appear to be the main cause of eosinophilic inflammation. IL-17 and Aeroallergens: Patients who were sensitive to firebush (p=0.003) and CCD indicators (p=0.005) had significantly higher levels of IL-17, suggesting that these allergens play a part in neutrophilic or mixed asthma phenotypes. Increased IL-17 in response to these allergens indicates the activation of non-Th2 pathways, especially in instances of severe asthma.

Limitations and Future Directions

The study highlighted the significance of environmental triggers in asthma exacerbations by identifying a number of aeroallergens with strong correlations to biomarker levels. IL-5 with Aeroallergens: Patients who were exposed to aeroallergens such white ash (p=0.006), sorrel (p=0.004), and sweet vernal mix (p=0.002) had higher levels of IL-5. According to these results, these allergens are important targets for allergen-specific immunotherapy as they appear to be the main cause of eosinophilic inflammation. IL-17 and Aeroallergens: Patients who were sensitive to firebush (p=0.003) and CCD indicators (p=0.005) had significantly higher levels of IL-17, suggesting that these allergens play a part in neutrophilic or mixed asthma phenotypes. Increased IL-17 in response to these allergens indicates the activation of non-Th2 pathways, especially in instances of severe asthma. A relatively small sample size may have an impact on the findings' generalizability; the study was cross-sectional, which limited the capacity to establish causal links. Environmental factors that may affect asthma phenotypes, like as pollution and food, were not thoroughly examined.

5. Conclusion

The significance of IL-5 and IL-17 as biomarkers for asthma phenotype in juvenile patients is highlighted by this study. IL-5 plays a crucial role in allergen-induced asthma, as seen by the strong association it has with particular allergens. Asthma treatment could be completely transformed by personalized therapy based on biomarker analysis.

References

Chu, D. K. et al. (2015) 'Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma', Allergy, Asthma & Clinical Immunology, 11, pp. 1–6.

Cookson, W., Moffatt, M. and Strachan, D. P. (2011) 'Genetic risks and childhood-onset asthma', *Journal of allergy and clinical immunology*, 128(2), pp. 266–270.

Hammad, H. and Lambrecht, B. N. (2021) 'The basic immunology of asthma', *Cell*, 184(6), pp. 1469–1485. Kim, Y., Vazquez, C. and Cubbin, C. (2023) 'Socioeconomic disparities in health outcomes in the United States in the late 2010s: results from four national population-based studies', *Archives of Public Health*, 81(1), p. 15.

Levy, M. L. *et al.* (2023) 'Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update', *NPJ primary care respiratory medicine*, 33(1), pp. 1–13.

Rahmawati, S. F. *et al.* (2021) 'Pharmacological rationale for targeting IL-17 in asthma', *Frontiers in allergy*, 2, p. 694514.

Ricciardolo, F. L. M. et al. (2023) 'Phenotype overlap in the natural history of asthma', European Respiratory Review, 32(168).

Takatsu, K. (2011) 'Interleukin-5 and IL-5 receptor in health and diseases', *Proceedings of the Japan Academy, Series B*, 87(8), pp. 463–485.

Wenzel, S. E. (2012) 'Asthma phenotypes: the evolution from clinical to molecular approaches', *Nature medicine*, 18(5), pp. 716–725.

Yang, X. et al. (2018) 'Neutrophilic asthma is associated with increased airway bacterial burden and disordered community composition', *BioMed research international*, 2018(1), p. 9230234.